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Target identification is a critical step in the lengthy and expensive process of drug development. Here, we describe
a genome-wide screening platform that uses systematic overexpression of pooled human ORFs to understand
drug mode-of-action and resistance mechanisms. We first calibrated our screen with the well-characterized drug
methotrexate. We then identified new genes involved in the bioactivity of diverse drugs including antineoplastic
agents and biologically active molecules. Finally, we focused on the transcription factor RHOXF2 whose overexpression
conferred resistance to DNA damaging agents. This approach represents an orthogonal method for functional
screening and, to our knowledge, has never been reported before.Background
Biological systems tend to remain phenotypically stable in
the face of environmental challenges and genetic changes
[1]. As such, genetic perturbation has become an efficient
technique to dissect cellular functions. In this study, we
used the concept of modulating gene dosage in human
cells to gain insight into drug mode of action. Understand-
ing the primary mechanism of action as well as the poten-
tial polypharmacological effects of a drug can provide
insight into how to reduce detrimental side effects, un-
cover new applications for novel indication and explain re-
sistance mechanisms [2-4].
Drug resistance in malignant tissues can be categorized
into three main mechanisms: (i) drug distribution/metabol-
ism (pharmacokinetics), (ii) heterogeneity of cancer cells
and (iii) tumor micro-environment [5,6]. Among the other
cellular mechanisms, gene overexpression (for example, by
amplification of the drug target) can titrate a drug’s effect.
This is exemplified by the classic case of methotrexate re-
sistance through the amplification of the gene DHFR in
neoplastic tissue from an individual with disseminated
small-cell lung cancer that relapsed during methotrexate
chemotherapy [7]. Other forms of overexpression resistance* Correspondence: corey.nislow@ubc.ca
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ATP-binding cassette transporters), 2) survival mechanisms
(for example, anti-apoptotic proteins), 3) DNA damage
repair, 4) pathways for drug inactivation and 5) the overex-
pression of target isotypes. Additionally, proteins down-
stream of the inhibited target can be modulated in such a
manner as to bypass the toxic effect of a drug.
To dissect some of these mechanisms by which drugs
act within the cell, we postulated that, when overexpressed,
genes conferring resistance to a lethal chemical treatment
can illuminate the drug mode of action. Overexpressing
genes to confer resistance to an otherwise toxic compound
is a well-established concept. Early studies showed that a
streptomycin resistance gene cassette could function in a
bacterial tetracycline resistant plasmid [8] and it was
shown in other studies that cloning of the mouse dihydro-
folate reductase into a bacterial plasmid provided resist-
ance to trimethoprim in Escherichia coli [9]. A large-scale
approach using the overexpression of a yeast genomic
DNA library to identify genes conferring resistance to spe-
cific drugs has validated the concept of gene dosage for the
discovery of drug targets in eukaryotes [10].
A logical extension of this concept is to employ newly
available biological tools that enable the systematic perturb-
ation of all protein function in human cultured cells using
RNA interference (RNAi), CRISPR (clustered regularly
interspaced short palindromic repeats), cDNA libraries,
transposons or small molecule inhibitors in combinationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapeutic drugs against all proteins from the approxi-
mately 20,000 genes of the human genome in all differenti-
ated cell types is not currently feasible, we report the initial
development of a gain-of-function approach to identify
drug mode of action by the overexpression of 12,200 hu-
man ORFs (hORFs) [11,12] in the human cell line HEK293.
In summary, we have developed a new experimental
pipeline to identify genes whose up-regulation suppresses
the toxic effect of chemicals in human cells and have suc-
cessfully applied this strategy to seven pharmacological
compounds.
Methods
Cell culture and plasmids
Human embryonic kidney HEK293 (ATCC), HEK293T
(ATCC), non-small cell lung carcinoma NCI-H1299 (ATCC),
chondrosarcoma SW1353 (gift from Johanne Martel-
Pelletier, University of Montreal, Canada) and pancreatic
adenocarcinoma HPAC (ATCC) cells were maintained
in DMEM (Wisent Inc. Montreal, Quebec, Canada) sup-
plemented with 10% fetal bovine serum (Gibco, Carlsbad,
California, US) at 37°C and 5% CO2. The rtTA express-
ing HEK293_M2 (ATCC), human breast adenocarcin-
oma MCF7_M2 (ATCC) and adenocarcinomic human
alveolar basal epithelial A549_M2 (ATCC) cells were
maintained in DMEM (Wisent Inc.) supplemented with
10% fetal bovine serum (Gibco) at 37°C and 5% CO2.
Blast phase chronic myelogenous leukemia K562 cells
(gift from Reinhart Reithmeier, University of Toronto,
Canada) were maintained in RPMI1640 (Sigma, St. Louis,
Missouri, US) supplemented with 10% fetal bovine
serum (Gibco) at 37°C and 5% CO2. Multiple myeloma
U266B1 cells (gift from Aaron Schimmer, Princess
Margaret Cancer Centre, Canada) were maintained in
Iscove's modified Dulbecco's medium (IMDM; Gibco) sup-
plemented with 10% fetal bovine serum (Gibco) at 37°C
and 5% CO2. Thyroid gland medullary carcinoma TT cells
(gift from Gilbert Cote, MD Anderson Cancer Center,
USA) were maintained in Ham’s F-12 K (Gibco) supple-
mented with 10% fetal bovine serum (Gibco) at 37°C and
5% CO2.
The lentiviral destination vector pLD-T-IRES-Venus-
WPRE-STOP was cloned using the following procedure:
the Gateway cassette from pLS-Dest-EcF (gift of Dr Tony
Pawson, University of Toronto, Canada) was subcloned into
pLJM17 (J Moffat, unpublished) using the restriction en-
zymes MluI and XbaI, resulting in the pLD-puro-TRE (T)
vector. IRES-Venus-WPRE were PCR amplified from the
pSLIK-Venus [13] using the following primers: XcmI_IR-
ES_F (5′-GCGCCTTTTCCAAGGCAGCCCTGGAATTC
CGCCCCTCTCCCTCC) and NsiI_WPRE_R (5′-AAACA
ATGCATGTCGACGCGGGGAGGCGGCCCAAAGGGA
GATCC). The IRES-Venus-WPRE amplicon was clonedinto the pLD-puro-T vector using the restriction en-
zymes XcmI and NsiI to replace the human phospho-
glycerate kinase promoter and puromycin resistance
gene. A stop codon was introduced directly downstream
of the Gateway cassette by digesting pLD-T-IRES-Venus-
WPRE with the restriction enzyme XbaI and blunted
using DNA polymerase I, large (Klenow) fragment (New
England Biolabs Inc., Beverly, Massachusetts, US).
The piggyBac PB-TGcMV-Neo plasmid used for the hit
confirmation was derived from the PB-TET (AddGene,
Cambridge, Massachusetts, US). The 'IRES-beta-Geo'
fragment from PB-TET was replaced by the 'promoter
PGK-neomycin resistance gene' fragment by homologous
recombination in Saccharomyces cerevisiae. Briefly, PB-
TET was digested with RsrII and ApaI to remove the
beta-geo gene. The fragment coding for the promoter
PGK and neomycin resistance gene, the URA3 cassette
and the yeast 2 μ-origin of replication were PCR amplified
and cloned into the digested PB-TET plasmid by homolo-
gous recombination in yeast. Yeast was then transformed
with the p414-Cre plasmid in order to excise the URA3
cassette and the 2 μ-origin of replication after expression
of the Cre recombinase.
All short hairpin RNAs (shRNAs) against the RHOXF2
and green fluorescent protein (GFP) mRNAs were de-
rived from the RNAi Consortium (TRC) lentiviral librar-
ies and obtained in the pLKO.1 vector. Five shRNAs
against RHOXF2 were tested and were designed against






Library preparation, virus production and lentiviral
infection
The 12,212 hORF collection (representing 10,214 distinct
genes) represents version 3.1 of an ongoing effort to create
a complete human set of protein-encoding genes [11,12].
Initially based on the Mammalian Gene Collection cDNA
collection, that work transfers full-length ORFs (excluding
the 5′ and 3′ mRNA untranslated regions) into a Gateway
system. Version 3.1 was obtained from Open Biosystems
(Thermo Scientific, Waltham, Massachusetts, US) and re-
groups non-fully sequenced verified and non-clonal ORFs
(limitations corrected in the 8.1 version [14]). The col-
lection was divided into 34 minipools of 376 hORFs;
for each minipool, the hORFs were cloned en masse
from the pDONR223 into the lentiviral expression vec-
tor pLD-T-IRES-Venus-WPRE-STOP by Gateway LR
reaction. After electroporation, transformants were se-
lected on Luria Broth (LB) plus ampicillin and the lenti-
viral vector was extracted.
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DNA for the 34 hORF minipools and by co-transfection
with the packaging plasmid psPAX2 and the envelope
plasmid pMD2.G into the packaging HEK293T cells using
FuGENE (Roche Mississauga, Ontario, Canada).
HEK293_M2 cells were then infected at a multiplicity of
infection of 0.3. Doxycycline (2 μg/ml) was added to in-
duce the expression of the Venus fluorescent protein and
Venus-positive cells were sorted using a BD FACS Aria
Cell Sorter (East Ruherford, New Jersey, US). Because the
expression of the gene coding for Venus is linked to the
expression of the hORFs, selection of the fluorescent cells
allowed the selection for non-silent, stably integrated
lentivirus as well as functional inducible hORFs.
Genomic DNA extraction, library preparation and data
analysis for the hORFeome representation in
HEK293_M2 cells
We thawed 6.3 × 106 HEK293_M2 cells harboring the
virally integrated human ORFeome version 3.1 collection
and these were cultured for 1 day to recover. Genomic
DNA was recovered from 16 × 106 cells and 6 μg of gen-
omic DNA (gDNA were used to amplify the collection
(three PCR reactions with 2 μg of gDNA). Following
PCR, the amplified ORFs were used directly to prepare
a Nextera sequencing library (Illumina Nextera DNA
Sample Preparation Kit, San Diego, California, US) and
sequenced on an Illumina MiSeq according to the man-
ufacturer’s protocol. Fifty-nucleotide paired-end reads
were aligned against a reference database consisting of
the ORF sequences in the hORFeome 3.1 collection
using bwa (version 0.6.1). Coverage at each base position
in each reference sequence was determined using the
bedtools program genomeCoverageBed (v2.14.2). A cus-
tom Perl script was used to summarize the coverage
levels to determine the mean coverage for each reference
sequence and the proportion of each reference sequence
with different levels of coverage. Raw data have been de-
posited in the ArrayExpress repository under accession
number E-MTAB-2498.
hORFeome drug target screen
Aliquots of 500,000 HEK293_M2 cells were seeded in a
T175 flask and grown for 15 hours before the induction of
hORF expression by addition of doxycycline. After 18 hours
of induction, cells formed micro-colonies that were cul-
tured in the presence of drug or DMSO (as control) for 2
to 3 weeks until distinct colonies were detectable.
After each screen, surviving cells were harvested and
gDNA was extracted as follows. Cells were lysed using
SNET buffer (10 mM Tris pH 8.0, 0.1 M EDTA, 0.5%
SDS, 0.1 mg/ml Proteinase K, 25 μg/ml RNAse A). gDNA
was isolated using one volume of phenol/chloroform/isoa-
myl alcohol (25:24:1) pH 8.0, precipitated by adding twovolumes of 95% ethanol (-20°C), washed with ice cold 70%
ethanol and resuspended in Tris-HCl pH 8.0.
During the screen selection experiments, only a minority
of hORFs protected HEK293_M2s against the cytotoxic
effect of the drug. Compared to the initial cell population,
HEK293_M2 cells harboring the most resistant genes
should be over-represented. In order to further amplify
the set of resistant genes from the resulting reduced popu-
lation, hORFs were PCR amplified from only 80 ng of gen-
omic DNA. The sequences of the forward and reverse
primers specific for the inserted hORFs were 5′-CGGT
ACCCGGGGATCCTCTAGTCAGCTGAC and 5′-CCAT
TTGTCTCGAGGTCGAGAATTCTAGCTAGAATC, re-
spectively. Each reaction was carried out in a 50 μl volume
containing 25 μl of 2× Phusion Flash High-Fidelity Master
Mix (Finnzymes, Espoo, Finland), 200 nM of each primer
and 80 ng of genomic DNA. The PCR profile was: 1 mi-
nute at 98°C for one cycle; 10 s at 98°C, 20 s at 65°C, 4 mi-
nutes at 72°C for 35 cycles; 10 minutes at 72°C for one
cycle. PCR products were purified using QIAquick PCR
Purification Kit (QIAGEN Venlo, Limburg, Netherlands),
150 ng of purified PCR product was biotinylated using
the BioPrime DNA Labeling Kit (Invitrogen, Carlsbad,
California, US) and unincorporated biotin-14-dCTP was
removed by passing the samples through Sephadex G-50
columns (GE Healthcare Fairfield, Connecticut, US).
Sample (150 ng) was added to the Affymetrix GeneChip
Human Gene 1.0 ST array and hybridized at 45°C for
17 hours with a rotation of 60 rpm. Chips were washed and
stained with SAPE (2× MES staining buffer, 20 mg/mL bo-
vine serum albumin (BSA) and 1 mg/ml streptavidin-
phycoerythrin), washed on an Affymetrix fluidics station
and scanned.
Representation of the complete hORFeome collection
was assessed using the same experimental conditions
with some modifications. gDNA was extracted from at
least 16 × 106 cells (approximately 1,300 cells per hORF),
3 PCR reactions were performed using 2 μg of gDNA
each (approximately 75 genomes per hORFs), two bio-
tinylation reactions were performed using 500 ng of
combined PCR products and 3.5 μg of sample was added
to an Affymetrix GeneChip Human Gene 1.0 ST array.
Microarray raw data have been deposited in the
ArrayExpress repository [15] under accession number E-
MTAB-2493.
Selection and individual validation of over-represented
hORFs
The hORFs conferring resistance to the drug were iden-
tified in a step-wise procedure. Screen results were first
visualized by plotting the log2 of the signal intensity for
each hORF retrieved via PCR from cells cultured in the
presence of drug (on the x-axis) and by plotting the log2
ratio of the signal intensity for each hORF of the cells
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tensity for each hORF of the cells grown in the presence
of DMSO (on the y-axis). Genes with a log2(drug/DMSO)
>3 and a log2(drug) >6 enrichment were then listed and
ranked. Primary hits selected for validation were those
previously enriched genes in common among the drug
screen replicates (at least two independent experiments).
For validation, 10,000 HEK293-M2 cells were seeded in
300 μl of DMEM plus 10% iFBS plus penicillin/strepto-
mycin in a 48-well plate pretreated with poly-L-lysine
(Sigma, P4832). After 12 hours of incubation, gene expres-
sion was induced by the addition of doxycycline (2 μg/ml
final concentration). After 18 hours of induction, drug
was added and cell growth was assessed 3 days after drug
addition by sulforhodamine B (SRB) assay as previously
described [16].
Immunostaining
The HEK293_M2 + RHOXF2 stable cell line (PB-TGcMV-
Neo) were seeded in an eight-well chamber slide (BD
Falcon, East Ruherford, New Jersey, US.) and cultivated
overnight in the presence or absence of doxycyclin (2 μg/ml
final). Cells were treated with 50 nM of mitomycin C for
2 days before fixation with 2% paraformaldehyde and
permeabilization with 0.3% Triton X-100. Cells were
blocked for 30 minutes with blocking/dilution buffer
(10% goat serum, 0.5% NP-40, 0.5% saponin, 1×
phosphate-buffered saline (PBS)) and incubated with the
anti-phospho-histone H2A.X (serine 139, clone JBW301;
Millipore, Billerica, Massachusetts, US) overnight at 4°C.
Cells were then incubated with an Alexa 546 anti-mouse
antibody for 1 hour at room temperature, incubated with
DAPI (0.8 μg/ml; Sigma) for 10 minutes and mounted
using ProLong Gold (Invitrogen). Images were captured
using a 40× dry objective. Nuclei and γ-H2A.X foci were
quantified using CellProfiler [17].
RNA extraction and library preparation for gene expression
profiling of the RHOXF2 overexpressing cell line
The HEK293_M2 + RHOXF2 stable cell line (PB-TGcMV-
Neo) was seeded in 10-cm dishes, cultivated 24 hours in
the presence or absence of doxycycline (2 μg/ml final) be-
fore being treated with 40 nM of mitomycin C or DMSO
(control) during a 2-day period. Total RNA was extracted
(RNeasy Mini Kit, QIAGEN), mRNA-focused libraries
were generated from 1 μg of total RNA (Illumina TruSeq
RNA Sample Preparation Kit V.2) and sequenced using an
Illumina HiSeq2000 according to the Illumina protocol.
Raw data have been deposited in the ArrayExpress reposi-
tory under accession number E-MTAB-2497.
RNA-sequencing data analysis
Single-end reads, 51 nucleotides in length, were gener-
ated on the Illumina HiSeq. Sequence data were alignedto the UCSC hg19 reference genome using TopHat
(v2.0.0), provided with a RefSeq GTF file and instructed
to align only across known junctions. Differential ex-
pression, as fragments per kilobase of exon per million
fragments mapped (FPKM) differences, were generated
by analysis with cuffdiff (v1.1.0) using the indicated com-
parisons. Based on their differential expression, potential
activated and repressed isoforms were identified and re-
lated enriched biological processes were assessed using
GOrilla [18].
RHOXF2 quantitative RT-PCR
Total RNA from 20 different normal human tissues
(each pool from 3 donors) were obtained from the First-
Choice Human Total RNA Survey Panel (Ambion, Austin,
Texas, US). Total RNA (5 μg) from each tissue was used
for oligo(dT)12-18-primed reverse transcription using the
SuperScript II reverse transcriptase (Invitrogen). Quantita-
tive PCR was performed using the LightCycler 480 SYBR
Green I Master (Roche) and the LightCycler 480 System
with the following primers:
QhRHOXF1_1F (5′-ACCGTGTTCTACTGCCTGAGT
GTA) and QhRHOXF1_1R (5′-TTCATGCCGTTCTCGT
GGTTCACA) on RHOXF1 exon 1; QhRHOXF1_2F (5′-T
GGAGGAGCTGGAAAGTGTT) and QhRHOXF1_2.2R
(5′-GGCCCTTTTATTCTTAAACC) spanning RHOXF1
exon 1 and exon 3; QhRHOXF2_1F (5′-CCGGACCAGT
GTAGCCAGTA) and QhRHOXF2_1R (5′-TCTTTTTCT
TCTCCGCCTTG) spanning RHOXF2 exon 1 and exon 2;
QhRHOXF2_2F (5′-ATGGTGCTGTCGCTTACTGA) and
QhRHOXF2_2R (5′-TCGAGGTCTCCTTCCCATAG) on
RHOXF2 exon 2; QhRHOXF2_4F (5′-CAGCGGGATGAG
AGATGATT) and QhRHOXF2_4R (5′-TTGGGGAATGT
GAAAGAAGG) on RHOXF2 exon 3.
Housekeeping/reference genes were: QhCYCG_F (5′-CT
TGTCAATGGCCAACAGAGG) and QhCYCG_R (5′-GC
CCATCTAAATGAGGAGTTGGT) on CYCG (cyclophilin
G); QhGUSB_F (5′-ACGCAGAAAATATGTGGTTGGA)
and QhGUSB_R (5′-GCACTCTCGTCGGTGACTGTT)
on GUSB (beta-glucuronidase); QhActbF1 (5′-GAAGTC
CCTTGCCATCCTAAAAG) and QhActbR1 (5′-AGGA
CTGGGCCATTCTCCTTA) on ACTB (beta-actin); QhEe-
f1a1F2 (5′-CTGAACCATCCAGGCCAAAT) and QhEef1a
1R2 (5′-AGCCGTGTGGCAATCCA) on EEF1A1 (eukary-
otic translation elongation factor 1 alpha 1); QhGAP
DH_F1 (5′-CATGAGAAGTATGACAACAGCCT) and
QhGAPDH_R1 (5′-AGTCCTTCCACGATACCAAAGT)
on GAPDH (glyceraldehyde-3-phosphate dehydrogenase).
RHOXF2 immunohistochemistry
Formalin-fixed, paraffin-embedded sections of human
normal testis were deparaffinized for 12 hours at 58°C
and rehydrated. Heat-induced epitope retrieval was in
sodium citrate buffer pH 6.0 using a pressure cooker
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(TBS) with 1% BSA. Sections were blocked in 10% goat
serum (Gibco) for 2 hours at room temperature. The
anti-RHOXF2 primary antibody (Sigma, HPA003314)
was used at a 1:150 dilution and incubated overnight at 4°C
in a humid chamber. Endogenous peroxidase activity was
suppressed by incubating the section in 0.3% H2O2 for
15 minutes. Horse radish peroxidase (HRP)-conjugated sec-
ondary antibody (anti-rabbit IgG-HRP; GE Healthcare) was
used at a 1:250 dilution and incubated for 1 hour at room
temperature. 3,3′-Diaminobenzidine (Abcam) was used as
chromogen. Sections were counterstained with Mayer’s
hematoxylin (Sigma) before dehydration and mounting.
Western blotting
For the detection of endogenous RHOXF2, total cell ly-
sates were prepared from 200,000 cells. Briefly, samples
were lysed in 2× SB loading buffer (60 mM Tris-HCl
pH6.8, 3% SDS, 10% glycerol, 0.05% bromophenol blue,
10% beta-mercaptoethanol) and subjected to SDS-PAGE
(12%). The RHOXF2-specific mouse polyclonal antibody
(Abcam, ab67811) and the tubulin specific rat antibody
(Abcam, ab6160) were used at a dilution of 1:800 and
1:40,000 respectively. Immunological complexes were vi-
sualized by enhanced chemiluminescence using HRP-
conjugated anti mouse or anti rat IgG.
Drug dose-response curves
K562 cells (100,000) were cultured in 600 μl of media in
a 48-well plate for 24 hours before the addition of di-
luted drug. Two days after drug treatment, the percent-
age of drug inhibition was assessed by counting K562
using a Coulter particle count and cell analyser and
compared to cells grown in the presence of DMSO only.
For the adherent HPAC, SW1353, and NCI-H1299 cell
lines, 5,000 cells were seeded in 300 μl of media in 96-
well plate and incubated for 24 hours prior to drug
addition. Following two days of drug treatment, the per-
centage of drug inhibition was estimated by SRB assay
[16] and compared to cells grown in DMSO as control.
Results
Development of the assay: DHFR and methotrexate
We developed an original phenotypic assay in which the
mammalian cell line HEK293_M2 was used to identify
hORFs capable of rescuing small molecule toxicity when
overexpressed (Figure 1; Additional file 1). As a proof of
concept, we rescued methotrexate toxicity by overex-
pression of its target, the gene encoding the enzyme
dihydrofolate reductase (DHFR).
We first cloned the human DHFR gene into the Gateway-
compatible lentiviral vector pLD-T-IRES-Venus-WPRE-
STOP where gene expression is under the control of the
Tet-On promotor (Additional file 2). After transductionof the rtTA-expressing cell line HEK293_M2 by lentivirus,
we detected a high level of protein in the presence of
doxycycline by western blotting (Figure 2a; Additional file
3). No protein was detected in the absence of doxycycline,
suggesting robust control of transgene expression. Cells
were next exposed to increasing doses of methotrexate in
the absence or presence of different doses of doxycycline.
Increasing levels of DHFR overexpression in HEK293_M2
cells rescued methotrexate toxicity in a dose-dependent
manner, demonstrating that the lentiviral construct was
functional (Figure 2b; Additional file 3).
We implemented our approach on a larger scale by
cloning, en masse, a pool of 376 random hORFs (including
DHFR) into the lentiviral vector. Corresponding lentivirus
were used to generate a population of HEK293_M2 cells
with the stably integrated hORFs. Gene expression was
induced as before by addition of doxycycline and cells
were exposed to a lethal concentration of methotrexate.
Ten days after treatment, surviving cells were harvested,
genomic DNA was extracted, and hORFs were PCR amp-
lified and hybridized on an Affymetrix GeneChip Human
Gene 1.0 ST array to determine which hORFs conferred
resistance to methotrexate. DHFR was found as the pre-
dominant gene in this pool of 376 hORFs whose overex-
pression provided resistance to methotrexate, validating
our strategy at the scale of several hundred pooled clones
(Additional file 4).
The same approach was next applied to the complete
collection of 12,212 hORFs. Here, we divided the collec-
tion into 34 minipools of 376 hORFs each, transferred
them en masse into the pLD-T-IRES-Venus-WPRE-STOP
lentivirus vector and then pooled 34 minipools together to
produce sufficient quantities of lentivirus for the infection
of HEK293_M2 cells at a multiplicity of infection of 0.3
(Figure 1). Because induction of the Venus marker is
dependent on hORF expression, addition of doxycycline
for 24 hours generated sufficient fluorescence to sort
those cells with stable lentivirus integration (Additional
file 5). The presence and relative abundance of the virally
integrated hORFs were assessed using next-generation se-
quencing. Based on the identification of at least 95% of
the sequence with a minimum of 10× coverage, 87% of
the mappable hORFs were considered as present in the
HEK293_M2 cells. Further analysis of the sequencing re-
sults demonstrated a size-dependent relative abundance
of the hORFs, with smaller clones being more represented
in the population (Additional file 6). An aliquot of 500,000
HEK293_M2 cells (an average of 41 cells per hORF) was
seeded in a T175 flask, and grown for 15 hours before
the induction of hORF expression by addition of doxy-
cycline. After 18 hours of doxycycline induction, cells
formed micro-colonies, which were cultured in the pres-
ence of methotrexate for 2 weeks. hORFs derived from
































Figure 1 A gain-of-function cell-based assay to characterize the mode of action of small chemical compounds. (a) A collection of 12,212
hORFs was cloned en masse into the lentiviral expression vector pLD-IRES-Venus-WPRE-STOP. The resulting constructs were used to produce
lentivirus and infect the rtTA-expressing cell line HEK293_M2 at a multiplicity of infection (MOI) of 0.3. Sorting of the Venus-positive cells resulted in the
isolation of human cells with the functional integrated lentiviral constructs. (b) After seeding, doxycycline (dox) was added to the cells in order to in-
duce the expression of the hORFs. After selection in the presence of a lethal dose of drug, surviving cells were harvested, gDNA extracted and the na-
ture of the hORFs providing resistance to the chemical identified after hybridization on microarray. NGS, next-generation sequencing.
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pool experiment, DHFR was the top gene conferring re-
sistance to methotrexate when overexpressed (Figure 2c).
These results encouraged us to test the same strategy for




























Figure 2 DHFR was identified as the top candidate during a large-sca
conditional expression of DHFR in HEK293_M2 cells. Addition of 4 ng/ml, 1
DHFR protein expression in the stable cell line HEK293_M2. Alpha tubulin w
0.0032 ng/ml of doxycycline has been omitted. (b) Single DHFR overexpres
coding for DHFR was cloned into the lentiviral vector and used to create s
response curves of the cells grown in the presence of an increasing conce
30, 60, 125, 250, 500 and 1,000 nM of methotrexate and compared with th
was quantified using a SRB assay. Errors bars represent the standard deviat
to methotrexate when overexpressed. HEK293_M2 cells harboring the 12,2
methotrexate. The nature of the hORFs conferring resistance to the drug w
in the cells cultured in the presence of methotrexate on the x-axis; and by
cultured in the presence of the drug divided by the signal intensity for eacScreens with additional drugs
We tested six additional diverse drugs, including the
antifolate aminopterin, the lipase inhibitor orlistat,
the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-
















le screen against methotrexate. (a) Immunoblotting showing the
6 ng/ml, 63 ng/ml and 2,000 ng/ml of doxycycline (dox) induced
as used as a loading control. For clarity, protein expression level at
sion rescued methotrexate toxicity in HEK293_M2 cells. The gene
table HEK293_M2 cells able to conditionally express DHFR. Dose-
ntration of doxycycline were calculated after 2 days of exposure to 15,
ose for cells cultured in the presence of DMSO as control. Cell survival
ion for triplicate assays. (c) Identification of genes conferring resistance
12 hORF collection were grown in the presence of a lethal dose of
as identified by plotting the log2 of the signal intensity for each hORF
plotting the log2 ratio of the signal intensity for each hORF of the cells
h hORF of the cells grown in the presence of DMSO on the y-axis.
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mitomycin C) based on the diversity of their mode of
action (Table 1).
Each drug was screened at least twice and the top hits
(those hORFs most enriched in the final sample of
cells; see Methods) were selected for validation. Of 123
candidates, we successfully cloned 120 hORFs into
the modified Gateway-compatible piggyBac vector PB-
TGcMV-Neo (Additional file 7) and generated 120 inde-
pendent HEK293_M2 stable cell lines. Protection against
the drug toxicity was assessed two days after culturing
cells in the presence of four concentrations of each drug
with or without doxycycline induction. Relative cell dens-
ities were compared with cells containing an empty vector
control construct and were quantified by SRB assay. A
total of 17 unique hits were confirmed to rescue their re-
spective drug toxicity (Table 2). The number of validated
hits varied considerably according to the compound, with
bleomycin and 17-DMAG having low validation rates (7%
and 3%, respectively) and, in contrast, cisplatin and mito-
mycin C having high validation levels (27% and 42%, re-
spectively) (Table 2). Several scenarios, both technical and
biological, may explain this modest confirmation rate.
First, PCR amplification of the hORFs from gDNA and
probe cross-hybridization on microarrays can be expected
to generate a certain percentage of false positives, despite
each screen having been performed in duplicate. Second,
since this version of the hORFeome library is not fullyTable 1 Characteristics of screened compounds
Drug name Screen concentration Category*
Methotrexate 60 nM Antimetabolites/ immunosuppressan
Aminopterin 20 nM Antimetabolites (discontinued)
Orlistat 20 μM Antiobesity preparations, excluding
diet products
Bleomycin 1 μM Cytotoxic antibiotics and related
substances
Cisplatin 2 μM Other antineoplastic agents
Mitomycin C 80 nM Cytotoxic antibiotics and related
substances
17_DMAG 70 nM Experimental Hsp90 inhibitorsequence verified, we speculate that some genes contain
mutations that impair proper expression. We attempted to
minimize the impact of mutations by restriction verifying
four independent colonies from the original pDONR233
bacterial stock, cloning positive clones as a pool for sub-
sequent cloning into the PB-TGcMV-Neo vector and
transfection into HEK293_M2 cells. Finally, the biological
mechanisms by which these agents work will influence the
number of hits obtained from each screen, and therefore
affect the number of hits that can be confirmed. For this
proof-of-principle study we chose to be conservative,
selecting more hits for validation at the cost of a high
false-positive rate.
Screens for the antifolates methotrexate and aminopterin
For the antifolate screens, the single confirmed ORF was
DHFR. This result highlights the fact that when a single
hORF confers a strong growth advantage, it can domin-
ate the other clones in the population and potentially
mask the detection of other potential protective genes.
One way to address this and potentially improve the dy-
namic range for this drug class would be to repeat these
screens with a pool of hORFs lacking DHFR.
Among the potential expected hits present in our col-
lection was the enzyme gamma-glutamyl hydrolase
(GGH), which catalyzes the removal of polyglutamates
from methotrexate. Therefore, overexpression of GGH
would be expected to decrease the intracellular presenceClinical use Known target(s) Reference
ts Antineoplastic DHFR [20]
Antirheumatic
Dermatologic agent
Dermatologic agent (phase I) DHFR, FPGS(?) [21]
Antineoplastic agent (phase II)
Anti-obesity agent LPL [22]
PNLIP [23]
FASN
Antineoplastic agent DNA [24]
LIG1
LIG3
Antineoplastic agent DNA [25]
Antineoplastic agent DNA [26]





Table 2 Validated hits
Drug Gene name Accession number Description Number of validated/tested
candidate genes
Methotrexate DHFR BC000192 Dihydrofolate reductase 1/3
Aminopterin DHFR BC000192 Dihydrofolate reductase 1/9
Bleomycin IMMT BC002412 Inner membrane protein, mitochondrial (mitofilin) 2/30
STX3 BC007405 Syntaxin 3
Cisplatin MAP2K1IP1 BC026245 Mitogen-activated protein kinase kinase 1 interacting protein 1 4/15
MMD BC026324 Monocyte to macrophage differentiation-associated
PTPN2 BC016727 Protein tyrosine phosphatase, non-receptor type 2
RHOXF2 BC021719 Rhox homeobox family, member 2
Mitomycin C C20orf54 BC009750 Chromosome 20 open reading frame 54 8/19
CCDC45 BC009518 Coiled-coil domain containing 45
ELF5 BC029743 E74-like factor 5 (ets domain transcription factor)
PTPN2 BC008244 Protein tyrosine phosphatase, non-receptor type 2
RHOXF2 BC021719 Rhox homeobox family, member 2
TMEM150 BC050466 Transmembrane protein 150
USPL1 BC038103 Ubiquitin specific peptidase like 1
ZFP64 BC012759 Zinc finger protein 64 homolog (mouse)
17-DMAG EIF4B BC073139 Eukaryotic translation initiation factor 4B 1/29
Orlistat MGLL BC006230 Monoglyceride lipase 2/18
PON3 BC070374 Paraoxonase 3
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efflux of methotrexate out of the cell and decreasing
cytotoxicity. However, GGH overexpression was demon-
strated to be insufficient to produce resistance to the
drug in a human fibrosarcoma (HT-1080) and a human
breast carcinoma (MCF-7) cell line [28].
DHFRL1 (dihydrofolate reductase like-1) consistently
appeared as a top hit for screens with both methotrexate
and aminopterin but failed to confer resistance when in-
dividually expressed in HEK293_M2 cells. Based on the
strong similarity between DHFR and DHFRL1 (a total of
14 non-synonymous changes), we hypothesized that the
observed unspecific signal was probably due to cross-
hybridization. Interestingly, a similar problem occurred
when the same strategy using the same hORFeome li-
brary was tested in the model organism S. cerevisiae.
Both DHFR and DHFRL1 were enriched in the screens
against methotrexate (and their expression confirmed at
the protein level) but only DHFR conferred methotrex-
ate resistance (data not shown).
Orlistat screens
Orlistat is a lipase inhibitor that reportedly targets LPL
(lipoprotein lipase), PNLIP (pancreatic lipase) and FASN
(fatty acid synthase). Although LPL is absent from our col-
lection, PNLIP and FASN are present. However, genes for
the latter two did not confer overexpression resistance.Our screen identified the gene coding for monoglycer-
ide lipase (MGLL) as a resistance hit. MGLL hydrolyzes
intracellular triglyceride stores in adipocytes and other
cells to fatty acids and glycerol. The enzyme might also
be involved in the hydrolysis of monoglycerides [29]. In
vitro experiments suggest that orlistat can inhibit the
MGLL-like activity in rat-cerebellar membranes and rat
cerebellar homogenate [30], rendering the human MGLL
a potential direct target for orlistat.
Another validated hit, PON3, is also involved in lipid
metabolism. The gene encodes paraoxonase 3, which
is secreted into the bloodstream and associates with
high-density lipoprotein. The protein can also rapidly
hydrolyze lactones and inhibit the oxidation of low-
density lipoprotein.
Bleomycin screens
Although the exact mechanism of action of bleomycin is
unknown, available evidence indicates that its main mode
of action is via the inhibition of DNA synthesis, with add-
itional evidence for its inhibition of RNA and, to a lesser
extent, protein synthesis [31].
We show that overexpression of IMMT (inner mem-
brane protein, mitochondrial) partially rescues bleomycin
toxicity. Bleomycin treatment induces damage of both nu-
clear and mitochondrial DNA [32]. A recent study demon-
strated that the mitochondrial localization of PARP-1
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the maintenance of mitochondrial DNA integrity [33]. The
authors also suggest that IMMT overexpression results in
an increase of PARP-1 in the extracellular compartment.
We therefore speculate that IMMT overexpression recruits
sufficient PARP-1 into the mitochondrion to maintain
mitochondrial DNA integrity and promote cell survival.
Cisplatin and mitomycin C screens
RHOXF2 and PTPN2 were found to suppress the tox-
icity of cisplatin and mitomycin C. Together with the
antifolates, these DNA damaging agents were the only
screens yielding identical hits. Also, as for methotrexate
and aminopterin, both these alkylating agents have the
same mechanism of action.
Another validated hit for mitomycin C, ZFP64 (zinc
finger protein 64 homolog), is noteworthy because it has
been shown to be potentially phosphorylated by ATM
and ATR, the major signal transducing kinases of the
DNA damage response in response to ionizing radiation
[34]. This observation is consistent with a potential role
for ZFP64 in the repair of DNA damage generated by
both alkylating agents and ionizing radiation.
RHOXF2 overexpression confers resistance to several DNA
damaging agents
Among the top candidates from the screens and confirma-
tions, we focused on RHOXF2, a relatively uncharacterized
member of the homeobox gene family, because this gene,
when overexpressed, provided resistance to both cisplatin
and mitomycin C. RHOXF2 clearly reduced drug-induced
toxicities when overexpressed in the HEK293_M2 cell line
treated with cisplatin (1 to 2.5 μM) or with mitomycin C
(20 to 80 nM). Rescue efficiency ranged from 45 to 60%
and 30 to 42%, respectively (Figure 3a). This observation
was confirmed using an independent cell biological assay
in which overexpression of this transcription factor signifi-
cantly reduced the formation of γ-H2A.X foci in cells
treated with 50 nM of mitomycin C for 2 days (Figure 3b).
We next asked if RHOXF2′s protective effect was re-
stricted to cisplatin and mitomycin C or if this gene, when
overexpressed, could also suppress the toxicity of DNA
damaging agents with different mechanisms of action. Ac-
cordingly, we assessed the cytotoxicity of antimetabolites
(methotrexate, 5-fluorouracil), a radiomimetic (bleomycin),
replication inhibitors (camptothecin, doxorubicin, etopo-
side), mitaplatin, 4-nitroquinoline-1-oxide and several ex-
perimental platinum anticancer agents (PT-ACRAMTU
(EN), PT-ACRAMTU(PN), PT-ATUCA, PT-AMIDIN) on
HEK293-M2 cells expressing or not the transcription factor
(Figure 3c; Additional file 8). With the exception of the
topoisomerase I inhibitor camptothecin, all drugs whose
toxicity was suppressed by RHOXF2 overexpression dir-
ectly bind to DNA to exert their effects.These observations motivated us to ask (i) if and how
RHOXF2, an uncharacterized transcription factor, mod-
ulates gene expression in HEK293_M2 cells and (ii) if
the nature of the regulated genes can illuminate the pro-
tective response to DNA damaging agents. We cultured
HEK293_M2 cells with or without overexpression of
RHOXF2 in the presence of 40 nM of mitomycin C
or DMSO (control) and profiled their transcriptional
response by RNA-seq. The sequencing data confirmed
the RHOXF2 transcript was absent in the uninduced
HEK293_M2 samples and verified its strong induction in
the presence of doxycycline regardless of the drug treat-
ment (Additional file 9). Neither RHOXF1 nor RHOXF2B
expression was affected by RHOXF2 overexpression
(Additional file 9). Interestingly, and despite their limited
number, Gene Ontology analysis of the genes whose
expression was induced during RHOXF2 overexpres-
sion showed that the most significantly enriched path-
ways are related to DNA damage processes (P < 7 × 10-5
and P < 3 × 10-4), stress response (P < 3 × 10-4), apop-
tosis (P < 4 × 10-4) and cell cycle (P < 7 × 10-4) (Figure 3d;
Additional file 9). As anticipated, in the absence of
RHOXF2 and the presence of mitomycin C, we found a
strong enrichment for genes related to the response to
stress (P < 3 × 10-5) and regulation of protein metabolic
process (P < 9.5 × 10-5). Finally, in the presence of RHOXF2,
genes involved in the regulation of signal transduction
(P < 4 × 10-4) were induced during drug treatment. There-
fore, we suggest that when treated with DNA damaging
agents, the protective effect conferred by overexpression
of RHOXF2 is due, in part, to its activation of several key
genes involved in the response to DNA damage.
Finally, we asked if the RHOXF2-dependent protective
effect observed in HEK293_M2 cells was restricted to
one cell type. We then tested if RHOXF2 overexpression
could confer resistance to the rtTA-expressing human
breast adenocarcinoma cell line MCF7_M2 and the
adenocarcinomic human alveolar basal epithelial cell
line A549_M2. As quantified by both a two-fold shift
in IC50 (44.91 μM to 88.17 μM) and by the 21% decrease
in toxicity at 3 μM, RHOXF2 overexpression protected
MCF7_M2 cells against cisplatin-mediated toxicity
(Additional file 10a). In the absence of RHOXF2, addi-
tion of doxycycline resulted in a modest increase in IC50
(41.06 μM to 58.59 μM; empty vector). The effect of
the vector alone, while detectable, is less than that ob-
served in the presence of RHOXF2. In contrast, although
RHOXF2 overexpression in A549_M2 cells provided
some apparent resistance (shift in IC50 from 448 nM to
1,099 nM), the measured effect was, in fact, largely due
to doxycycline (shift in IC50 from 718 nM to 1,454 nM
with empty vector) (Additional file 10b). In conclusion,
our experiments suggest that the protective effect of
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Drug Type* Mode of action RHOXF2 
overexpression rescue
Cisplatin Other antineoplastic agents DNA cross linking, alkylation Rescue
MitomycinC Cytotoxic antibiotics and related substances DNA cross linking, alkylating like Rescue
Mitaplatin None Bind to nuclear DNA and mitochondrial pyruvate dehydrogenase Rescue
PT-ACRAMTU(EN) None Bind DNA Rescue
PT-ACRAMTU(PN) None Bind DNA Rescue
PT-ATUCA None Bind DNA Rescue
Camptothecin None Topoisomerase I inhibitor Rescue
Methotrexate Antimetabolites, Immunosuppressants Inhibit the metabolism of folic acid No rescue
5-fluorouracil Antimetabolites Pyrimidine analog, irreversible inhibition of thymidylate synthase No rescue
Bleomycin Cytotoxic antibiotics and related substances Intercalation or interaction with DNA minor groove No rescue
Doxorubicin Cytotoxic antibiotics and related substances Intercalating DNA, inhibition of topoisomerase II progression No rescue
Etoposide Plant alkaloids and other natural products Topoisomerase II inhibitor No rescue
Hydroxyurea Other antineoplastic agents Ribonucleotidereductase inhibition No rescue
4 -nitroquinoline -1-oxide None DNA adduct forming agent No rescue
PT-AMIDIN None Bind DNA No rescue
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Figure 3 RHOXF2 overexpression in HEK293_M2 cells conferred resistance to a wide variety of DNA damaging agents. (a) In HEK293_M2
cells, RHOXF2 overexpression rescued cisplatin and mitomycin C toxicity. Stable RHOXF2-expressing cells were cultured in the presence of an
increasing concentration of cisplatin or mitomycin C and their growth was compared to stable cells with the empty vector PB-TGcMV-Neo.
The effect of RHOXF2 expression on cell viability was measured two days after drug exposure and compared to cells cultured in the absence
of drug as a 100% viability control. P < 0.05, TukeyHSD test: *significant difference between RHOXF2 vector with and without doxycycline
(dox); **significant difference between RHOXF2 vector with doxycycline and empty vector with doxycycline. Error bars represent standard error
of the mean (n = 4). (b) Reduction in the number of γ-H2A.X foci by RHOXF2 overexpression in HEK293_M2 cells. Cells expressing or not
RHOXF2 were treated with 50 nM of mitomycin C (approximately IC10) for 2 days and stained for the presence of γ-H2A.X foci. Following
RHOXF2 overexpression, the number of γ-H2A.X foci per nucleus dropped from 20.71 ± 1.49 to 15.73 ± 0.92 (24% rescue). Nuclear DNA was
stained with DAPI. Quantification of γ-H2A.X foci in >250 cells from triplicate experiments. Scale bar: 10 μm. (c) In HEK293_M2 cells, RHOXF2
overexpression conferred resistance to various DNA damaging agents. RHOXF2 drug suppression capacity was tested using DNA damaging
agents with various modes of action as previously described for cisplatin and mitomycin C. (d) Gene Ontology analysis of upregulated genes
in HEK293_M2 cells. Cells expressing or not RHOXF2 were treated with 40 nM of mitomycin C for 2 days. Based on their P-values, the most
enriched biological processes are shown.
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http://genomemedicine.com/content/6/4/32and expression of the transcription factor is sufficient to
protect both HEK293 and MCF7 cells against the DNA
damaging agent cisplatin. As with all large-scale screens,
the biological significance of this observation should be
further confirmed, for example, by interrogating a larger
panel of cell lines.
Based on its viability and transcriptional phenotypes in
HEK293_M2 cells, we further investigated the potential
role for RHOXF2 in neoplastic cells.In normal tissue, RHOXF2 expression is confined to testis
but RHOXF2 is expressed in several cancer cell lines
In a small-scale study performed by northern blot analysis
on normal tissues, expression of the transcription factor
RHOXF2 was initially reported to be restricted to testis
[35]. We performed a large-scale systematic survey interro-
gating a more representative panel of 20 different normal
human tissues (3 donors per tissue type) by quantitative

















































































































































Figure 4 RHOXF2 is expressed in various cancer cell lines and modulates K562 resistance to DNA damaging agents. (a) In normal
human tissues, RHOXF2 was exclusively detected in testis. Total RNA from 20 distinct tissues (mix of 3 different donors) was reverse transcribed
into first strand cDNA and used as template for quantitative PCR. Three distinct pairs of primers covering exons 1, 2 and 4 were used. RHOXF2
expression level was calculated relative to the signal obtained for the amplification of housekeeping genes (CYCG, GUSB, ACTB, EEF1A1, GAPDH).
(b) Representative example of immunohistochemical staining for RHOXF2 in normal testis. Section has been counterstained with Mayer’s
hematoxylin. (c) RHOXF2 was detected in various tumor cell lines by western blotting. (d) RHOXF2 shRNA validation in the human chronic
myelogenous leukemia cell line K562. WT, wild type. (e,f) Partial depletion of RHOXF2 increased K562 sensitivity to cisplatin and mitomycin C.
Final numbers of viable cells were calculated in the absence of drug (inset). Student’s t-test; *P < 0.05; **P < 0.01; means ± standard error of the
mean for n = 4 experiments.
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types expressed RHOXF2 protein by immunohistochemis-
try on normal testis samples. We detected a strong signal
for RHOXF2 in spermatogonia and primary spermatocytes
but not in spermatids (Figure 4b). Because RHOXF2 gene
expression was detected in early stage spermatogenic cellsand not in later stages, we hypothesized that RHOXF2
might be involved in the self-renewal or maintenance of
the undifferentiated state of the testis germ cells.
Computational analysis predicts RHOXF2 to be a tes-
ticular cancer candidate gene [36] and, in fact, the tran-
script was detected in several types of human testicular
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http://genomemedicine.com/content/6/4/32cancers [37]. Furthermore, in the present study, we show
that RHOXF2 overexpression conferred resistance to cis-
platin (Figure 3a) and that RHOXF2 is found in several
other cancer cell lines, the non-small cell lung carcin-
oma NCI-H1299, the blast phase chronic myelogenous
leukemia K562, the multiple myeloma U266B1, the thy-
roid gland medullary carcinoma TT (CRL-1803) and the
chondrosarcoma SW1353 (Figure 4c; Additional file 11).
In the chronic myelogenous leukemia K562 cell line,
RHOXF2 depletion modulates the response to
antineoplastic agents
Our study showed that RHOXF2 overexpression confers
resistance to cisplatin and mitomycin C in HEK293_M2
cells, in which the protein is not endogenously expressed
(Figure 4c; Additional file 9). We first generalized this
observation by positing that overexpression or ectopic ex-
pression of certain genes greatly reduces some detrimental
drug effects on the growth of particular cancer cell lines.
We then reasoned that if this is truly drug-gene specific,
the opposite mechanism should experimentally verify
it. More specifically, depletion of the endogenously
expressed protein should confer sensitivity to the cell line
during drug treatment. The most direct translation of this
gene-drug specificity could then be exploited to under-
stand drug resistance in cancer cell lines. Therefore, we
asked if sensitivity to DNA damaging agents was observed
when RHOXF2 is knocked down in cancer cells where
the protein is normally expressed. We generated several
stable cell lines to deplete RHOXF2 (NCI-H1299, K562,
SW1353, and the human pancreatic HPAC as negative
control) with five shRNAs that target the mRNA. Two
shRNAs against GFP were used as a negative control. Two
shRNAs showed a strong knock-down of the protein in all
three RHOXF2-positive cell lines (Figure 4d; Additional
file 12e,h).
K562 showed a significant increase in sensitivity for
both cisplatin (IC50: 3.231 μM to 2.052 μM) and mitomy-
cin C (IC50: 377.8 nM to 250.4 nM) when the transcrip-
tion factor was depleted, demonstrating the potential
role of RHOXF2 in response to DNA damaging agents
and particularly in response to DNA crosslinking agents
(Figure 4e,f). Independent K562 transduction resulted in
identical sensitivity to the drugs, showing the phenotype is
independent of the lentiviral integration site. We ruled out
the possibility that the calculated drug sensitivity simply
reflected a growth difference among cell lines by demon-
strating that the RHOXF2_shRNA and GFP_shRNA con-
trol cell lines divided at the same rate (Figure 4e,f, insets).
Finally, we assessed the robustness of our knock-downs in
the presence of the drugs by confirming that the modula-
tion of RHOXF2 protein level is maintained even when
the K562 cells were exposed to cisplatin or mitomycin C
at IC70 (Additional file 13a,b).As expected, no change was measured for the RHOXF2-
negative HPAC cells (Additional file 12a,b). Interestingly,
no increase in sensitivity to cisplatin and mitomycin C was
observed for NCI-H1299 and SW1353 knock-down cell
lines (Additional file 12c,d,f,g).
The modest increase in sensitivity of K562 cells to DNA
damaging agents can be explained by different factors.
First, transcription factors are generally present in limited
quantities in cells [38-40]. Here, although clearly depleted
in the presence of the shRNAs, RHOXF2 is still present
at a relatively high level in K562 cells (Figure 4d). There-
fore, we speculate that despite the efficient knock-down,
the limited shift in IC50 is in part due to the presence of
enough protein to sustain a certain level of resistance dur-
ing drug treatment. In order to test our first hypothesis,
a complete knock-out of the transcription factor would
be necessary (for example, using CRISPR technology).
Secondly, a recent study in mouse embryonic stem cells
reports that knock-down of a few transcription factors
is associated with substantial transcriptome change [41].
These data not only indicate the robustness of the pluripo-
tency gene network but also suggest that perhaps RHOXF2
knock-down hardly perturbs the transcription factor net-
work in the K562 cellular context.
Discussion
We have reduced to practice an elegant method to simul-
taneously evaluate thousands of genes for their capacity to
provide a survival advantage in the presence of a toxic
dose of drug using cells expressing the entire hORF collec-
tion and a microarray or sequencing-based readout.
The availability of hORF collections represents great
progress compared to traditional approaches (random
mutagenesis, cDNA libraries, and so on) because it per-
mits the systematic interrogation of a gene's biological
function in a targeted manner. Such gain-of-function ap-
proaches would be bolstered when combined with the
reciprocal loss-of-function approach [42]. To date, sev-
eral studies have already explored the availability of such
collections. Most of the studies tested the hORFs func-
tion in an array (well-based) format [43-45] that simpli-
fies the readout and analysis of the results. Here, we
tested the function of thousands of ORFs simultaneously
in a competitive manner. Our pool approach greatly re-
duced the tedious and expensive upstream steps of clon-
ing, transduction and testing of the genes. The primary
challenges to the pool approach are (i) potential loss of
ORFs during cloning and infection (leading to represen-
tation variability), (ii) the potential masking effect of
overrepresented clones in a population during selection
(for example, DHFR in the case of methotrexate) and
(iii) the necessity for dedicated analysis of the final results
(hits prioritization). In addition to future enhancements of
the human ORFeome collection, other promising gain-of-
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the development of functional variomics technology
[46] and the exploration of human isoform space in hu-
man cell lines.
In developing the assay, we first determined the opti-
mal period of time between the beginning of the gene
expression and the addition of the chemical compound.
To address that question, we quantified the number of
Venus-positive cells 12 hours, 24 hours and 48 hours
after induction of expression of the hORF collection. Be-
cause the human gene and the Venus marker are co-
transcribed, quantifying the level of Venus expression by
flow cytometry serves as a proxy for the level of human
gene expression. Because the number of Venus-positive
cells peaks at 24 hours after doxycycline addition
(Additional file 5), we postulated that 18 hours post-
induction would be sufficient time after which to add
drug to test the human gene for any protective effects.
We then addressed the sensitivity of the technique by
improving the ratio between the number of seeded cells,
the growth area and the time of drug addition. Seeding
500,000 cells in a T175 flask 33 hours before drug
addition provided enough time and density for isolated
cells to form separate micro-colonies that should over-
express only one or a few genes. This 'clonogenic assay
approach' was more sensitive to lower drug concentra-
tions and provided a better selective environment for
the surviving cells, presumably by minimizing signaling
from a large population of dying cells that would arise at
higher plating densities. Similarly, adding fresh medium
and drug every 48 hours for the duration of the screen
improved the selection process by washing away the
dead and dying adherent cells that could have interfered
with the subsequent screen readout.
During the course of the screen, the cell population
followed a stereotypical pattern of growth, starting with
a dramatic decrease in cell number and disappearance of
the majority of cells, followed by a stabilization of the
population and concluding with the development of
medium to large size colonies originating from the initial
surviving cells. Daily visual inspection of the cell popula-
tion was crucial to determine when to stop the drug se-
lection and harvest the cells, typically after 20 to 30
doubling times.
Several refinements may enhance this assay. First, im-
proving the coverage and expression quality of the hu-
man genes using a more complete collection of fully
sequenced ORFs as such collections become available
[14]. Moreover, as illustrated in Additional file 6, relative
abundance of the virally integrated hORFs is size-
dependent. Therefore, to correct for that variation, prep-
aration of the normalized amount of plasmid DNA for
lentivirus production could be done as follows: i) reduce
the pool size (less than 376 hORFs per pool as in ourstudy); ii) hORFs should be grouped by gene length. One
can also match the particular drug under interrogation
to disease-appropriate cell types and environmental
conditions. Whenever possible, experiments should be
performed with an initial high number of cells to guar-
antee the full representation of the collection during
drug target screening. Although DNA damaging resist-
ance was observed in the RHOXF2-overexpressing
HEK293_M2 cells, it would be informative to further
study if that observation is dependent on RHOXF2 ex-
pression status. Finally, next-generation sequencing will
facilitate the throughput of hit detection and reduce
the number of false positives arising from microarray
cross-hybridization.
Our study revealed several genes whose functions re-
late to the action of the drugs tested. RHOXF2 is of a
particular interest because of (i) its strong rescue pheno-
type in HEK293_M2 cells, (ii) its capacity to suppress
both cisplatin and mitomycin C toxicity, and (iii) the
dearth of functional information on this transcription
factor. Homeobox genes encode transcription factors
that play a central role during embryogenesis. RHOXF2
belongs to the Rhox family of genes, which are expressed
not only during embryogenesis but also in adult repro-
ductive tissue [47]. In normal tissue, RHOXF2 expres-
sion is likely restricted to testis but its function remains
largely unknown [35,48]. Here, we demonstrated that (i)
the presence of RHOXF2 was sufficient to lower both
cisplatin and mitomycin C toxicity in HEK293_M2 cells,
and (ii) the transcription factor might exert its effect via
the activation of genes involved in response to DNA
damage. Furthermore, RHOXF2 protein expression was
detected in several cancer cell lines. In one of these lines
(chronic myelogenous leukemia/K562) knocking down
the protein increased the toxicity for both DNA dam-
aging agents. Interestingly, although no growth disad-
vantage was observed in K562 cells partially depleted
for RHOXF2 (Figure 4e,f ), its depletion via shRNA in-
creased the sensitivity of this leukemia cell line to several
pharmacological compounds. We therefore speculate
that although not a driver of tumorigenesis, RHOXF2
could confer on the neoplastic cells a selective advantage
during drug treatment.
Conclusions
We demonstrate the usefulness of our approach in order
to understand drug mechanisms of action by combining
genetic perturbation with drug treatment. Here we reca-
pitulated examples of drug resistance and uncovered
several unanticipated drug-target interactions by virtue
of the suppression of chemical toxicity observed upon
gene overexpression. We also provide a step-by-step
protocol for performing such screens and for analyzing
the data (Additional file 1). Moreover, our innovative
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genes whose up-regulation could be toxic or enhance cell
proliferation in different cell types. For example, the assay
could be useful to uncover tumor-specific activity in the
context of genome engineering as well as for the discovery
of cell-type-specific oncogenes.Additional files
Additional file 1: Step-by-step protocol for a genome-wide
mammalian overexpression drug screen.
Additional file 2: Plasmid map of the lentiviral vector pLD-T-IRES-
Venus-WPRE-stop.
Additional file 3: Original immunoblotting showing the conditional
expression of DHFR in HEK293_M2 cells. Addition of 4 ng/ml, 16 ng/ml,
32 ng/ml, 63 ng/ml and 2,000 ng/ml of doxycycline induced DHFR protein
expression in the stable cell line HEK293_M2. Expression level was compared
to alpha tubulin as a loading control. The asterisk marks a human protein
that cross-reacts with the anti-DHFR antibody.
Additional file 4: DHFR was identified as the predominant gene in
this pool of 376 hORFs whose overexpression provided resistance
to methotrexate. HEK293_M2 cells harboring a minipool collection of
376 hORFs (including DHFR) were grown in the presence of a lethal dose
of methotrexate. The nature of the hORFs conferring resistance to the
drug was identified by plotting the log2 of the signal intensity for each
hORF in the cells cultured in the presence of methotrexate on the x-axis;
and by plotting the log2 ratio of the signal intensity for each hORF of the
cells cultured in presence of the drug divided by the signal intensity for
each hORF of the cells grown in presence of DMSO on the y-axis.
Additional file 5: Detection of Venus-expressing HEK293_M2 cells
after 12, 24 and 48 hours of induction. (a,b) HEK293_M2 cells stably
transduced with the hORFeome collection (b) or not (a) were cultured in
the presence of doxycycline (2 μg/ml) for 12, 24 and 48 hours. After gene
induction, cell number and intensity of the Venus fluorescence were
measured by flow cytometry. The percentage of Venus positive cells was
compared to the total number of living cells measured.
Additional file 6: Human ORFeome relative abundance in
HEK293_M2s at T0.
Additional file 7: Plasmid map of the transposon-based vector
PB-TGcMV-Neo.
Additional file 8: In HEK293_M2 cells, RHOXF2 overexpression
conferred resistance to various DNA damaging agents. Stable RHOXF2
cells was cultured in the presence of an increasing concentration of DNA
damaging agents and their growth was compared to the stable cells with
the empty vector PB-TGcMV-Neo. The effect of RHOXF2 expression on
cell viability was measured two days after drug exposure and compared to
cells cultured in the absence of drug as a 100% viability control. TukeyHSD
test, P < 0.05; *significant difference between RHOXF2 vector with and
without doxycycline; **significant difference between RHOXF2 vector with
doxycycline and empty vector with doxycycline. Error bars represent
standard error of the mean (n = 4).
Additional file 9: RHOXF2 raw FPKM values and Gene Ontology
enrichment.
Additional file 10: RHOXF2 overexpression rescued cisplatin toxicity
in HEK293_M2 and MCF7_M2 but not A549_M2 cells. Stable RHOXF2
cells were cultured in the presence of an increasing concentration of
cisplatin and their growth was compared to the stable cells with the empty
vector PB-TGcMV-Neo. The effect of RHOXF2 expression on cell viability
was measured three days after drug exposure and compared to cell
cultured in the absence of drug as a 100% viability control. Lines show the
nonlinear fit of a variable-slope dose-response model for (a) MCF7_M2 cells,
(b) A549_M2 cells and (c) HEK293_M2 cells as positive control; (d) resulting
IC50s. Data analysis was performed using the 'drc' package in R. Experiments
were done in triplicate.Additional file 11: RHOXF2 was detected in various tumor cell lines
by western blotting.
Additional file 12: RHOXF2 knocked-down in HPAC, NCI-H1299 and
SW1353 cells does not modulate cisplatin and mitomycin C
sensitivities. (a-g) Dose-response curves for HPAC (a,b), NCI-H1299 (c,d)
and SW1353 (f,g) were established after 2 days of exposure to cisplatin
(a,c,f) or mitomycin C (b,d,g). Percentage of growth inhibition was
calculated by comparing the number of cells treated with drug to the
number of cells cultured in media with DMSO as control. Error bars
represent standard error of the mean (n = 4). RHOXF2 depletion in
NCI-H1299 (e) and SW1353 cells (h). Total cell extracts for each cell line
were used to detect the presence of RHOXF2 by western blotting.
Expression level was compared to the alpha tubulin as loading control.
Additional file 13: RHOXF2 knocked down in K562 cells. (a,b) Cell
lines in which RHOXF2 and GFP were knocked down were grown in the
presence of 35 μM cisplatin (a) or 7 μM of mitomycin C (b) for 2 days.
Total cell extracts for each cell line were used to detect the presence of
RHOXF2 by western blotting. Expression level was compared to alpha
tubulin as loading control. (c) Total cell extracts from a RHOXF2-expressing
cell line and a cell line with GFP knocked down but overexpressing RHOXF2
were used to detect the presence of RHOXF2 by western blotting.
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